Patents by Inventor Katsumasa Nakajima
Katsumasa Nakajima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970497Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.Type: GrantFiled: July 31, 2020Date of Patent: April 30, 2024Assignee: Novartis AGInventors: Chris Adair, Tracy Chen, Jian Ding, Christy Fryer, Yuko Isome, Marie-Helene Larraufie, Katsumasa Nakajima, Nik Savage, Ariel Sterling Twomey
-
Patent number: 11958846Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.Type: GrantFiled: August 12, 2019Date of Patent: April 16, 2024Assignee: Novartis AGInventors: Christopher Adair, Katsumasa Nakajima, Rukundo Ntaganda, Julien Papillon, Troy Douglas Smith
-
Publication number: 20240042051Abstract: Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.Type: ApplicationFiled: November 23, 2021Publication date: February 8, 2024Inventors: Matthew T. Burger, Zhuoliang Chen, Joseph Anthony D'Alessio, Claudia Judith Klinter, Eric McNeill, Cornelia Anne Mundt, Katsumasa Nakajima, Richard Vaughan Newcombe, Mark G. Palermo, Tamas Schweighoffer, Bing Yu, Katharina Winkelbach, Qiang Zhang, Laura Bresson, Frédéric Colland, Ana Leticia Maragno, Francesca Rocchetti
-
Publication number: 20230092679Abstract: Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.Type: ApplicationFiled: May 19, 2020Publication date: March 23, 2023Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio
-
Publication number: 20230091510Abstract: Provided herein are linkers, linker-drug groups and anti-body-drug conjugates comprising hydrophilic groups.Type: ApplicationFiled: May 19, 2020Publication date: March 23, 2023Inventors: Zhuoliang CHEN, Katsumasa NAKAJIMA, Matthew T. BURGER, Joseph Anthony D'ALESSIO, Eric MCNEILL, Mark G, PALMERO, Bing YU, Qiang ZHANG
-
Publication number: 20230081720Abstract: Anti-CD74 antibody-drug conjugates are disclosed. The anti-CD74 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD74 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.Type: ApplicationFiled: May 19, 2020Publication date: March 16, 2023Inventors: Matthew T. Burger, Maia Chanrion, Frédéric Colland, Marton Csekei, Lea Delacour, Patrice Desos, Olivier Geneste, Jean-Michel Henlin, Vesela Kostova, Andras Kotschy, Ana Leticia Maragno, Eric McNeill, Mark G. Palermo, Francesca Rocchetti, Jérôme Starck, Bing Yu, Qiang Zhang, Ágnes Proszenyák, Szabolcs Sipos, Zhuoliang Chen, Katsumasa Nakajima, Joseph Anthony D'Alessio, John William Blankenship
-
Publication number: 20220315582Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.Type: ApplicationFiled: July 31, 2020Publication date: October 6, 2022Inventors: Chris ADAIR, Tracy CHEN, Jian DING, Christy FRYER, Yuko ISOME, Marie-Helene LARRAUFIE, Katsumasa NAKAJIMA, Nik SAVAGE, Ariel Sterling TWOMEY
-
Patent number: 11377656Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.Type: GrantFiled: March 8, 2017Date of Patent: July 5, 2022Assignee: Novartis AGInventors: Shari Lynn Caplan, Katsumasa Nakajima
-
Publication number: 20210323956Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.Type: ApplicationFiled: August 12, 2019Publication date: October 21, 2021Inventors: Christopher ADAIR, Katsumasa NAKAJIMA, Rukundo NTAGANDA, Julien PAPILLON, Troy Douglas SMITH
-
Publication number: 20190100752Abstract: This invention provides messenger RNA (mRNA) molecules comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), (II), and (III), gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of mRNA molecules.Type: ApplicationFiled: March 8, 2017Publication date: April 4, 2019Inventors: Shari Lynn CAPLAN, Katsumasa NAKAJIMA
-
Patent number: 8703761Abstract: The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.Type: GrantFiled: July 14, 2009Date of Patent: April 22, 2014Assignee: Novartis AGInventors: Cornelia Jutta Forster, Young-Shin Kwak, Katsumasa Nakajima, Bing Wang
-
Patent number: 8084448Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: GrantFiled: March 29, 2007Date of Patent: December 27, 2011Assignee: Novartis AGInventors: Alan Neubert, David Barnes, Young-Shin Kwak, Katsumasa Nakajima, Gregory Raymond Bebernitz, Gary Mark Coppola, Louise Kirman, Michael H. Serrano-Wu, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda, James Richard Wareing
-
Patent number: 7700633Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: GrantFiled: December 6, 2006Date of Patent: April 20, 2010Assignee: Novartis AGInventors: David Barnes, Gregory Raymond Bebernitz, Gary Mark Coppola, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda, James Richard Wareing, Katsumasa Nakajima
-
Publication number: 20100022513Abstract: The invention relates to compounds of formula (I): where A is an optionally substituted heteroaryl, useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.Type: ApplicationFiled: July 14, 2009Publication date: January 28, 2010Inventors: Cornelia Jutta Forster, Young-Shin Kwak, Katsumasa Nakajima, Bing Wang
-
Publication number: 20090181928Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: ApplicationFiled: March 29, 2007Publication date: July 16, 2009Inventors: Alan Neubert, David Barnes, Young-Shin Kwak, Katsumasa Nakajima, Gregory Raymond Bebernitz, Gary Mark Coppola, Louise Kirman, Michael H. Serrano-Wu, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda, James Richard Wareing
-
Publication number: 20080293782Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: ApplicationFiled: December 6, 2006Publication date: November 27, 2008Inventors: David Barnes, Gary Mark Coppola, Robert Edson Damon, Katsumasa Nakajima, Brian Christopher Raudenbush, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda
-
Publication number: 20080262050Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: ApplicationFiled: December 6, 2006Publication date: October 23, 2008Inventors: David Barnes, Gregory Raymond Bebernitz, Gary Mark Coppola, Katsumasa Nakajima, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda, James Richard Wareing